Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Hodgkin Disease 35 Lymphoma 18 Urinary Bladder Neoplasms 10 Neoplasms 3 Melanoma 3 Leukemia 2 HIV Infections 2 Glioma 2 Carcinoma, Renal Cell 2 Breast Neoplasms 2 Urothelial Carcinoma of the Bladder 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Survival Without Progression 1 Skin Neoplasms 1 Sarcoma 1 Rhabdoid Tumor 1 Recurrence 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precancerous Conditions 1 Pathologic Complete Response 1 Neurofibromatosis 1 1 Neurofibroma, Plexiform 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Mesothelioma, Malignant 1 Lymphoma, Large-Cell, Anaplastic 1 Lung Neoplasms 1 Kidney Neoplasms 1 Desmoid Tumors 1

Interventions

Vinblastine 1 Methotrexate 1 Cyclophosphamide 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Survival Without Progression × Vinblastine × Clear all

NCT01285817 2023-03-13

SFCE METRO 01

Assistance Publique Hopitaux De Marseille

Phase 2 Completed

Survival Without Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡